INTRODUCTION
============

The incidence of endometrial cancer among malignant gynecological tumors has increased with lifestyle and environmental changes, and has reached almost half of all cases of uterine cancer in Western countries. The absolute number and prevalence of cases of endometrial cancer have increased worldwide and control of this cancer is an urgent task. However, many aspects of the mechanism of carcinogenesis and pattern of advancement are unclear. Environmental factors such as obesity and a high estrogen level are thought to play important carcinogenic roles, but a close association with hereditary disposition has also been suggested, since double cancer and an increased incidence of cancer in relatives are common in patients with endometrial cancer.

A high incidence of concomitant endometrial cancer has been shown in female patients with hereditary nonpolyposis colorectal cancer (HNPCC), a typical familial tumor that is inherited in an autosomal dominant manner, indicating the presence of HNPCC-associated familial endometrial cancer. HNPCC has a high risk of development of colorectal cancer, and accumulation of colorectal cancer in a family line was initially reported by Wartin *et al*. in 1913. Subsequent analysis of this family led Lynch to propose the disease concept of cancer family syndrome in 1971 \[[@R1],[@R2]\]. In 1990, the International Collaborative Group (ICG)-HNPCC established the following clinical diagnostic criteria for HNPCC, which are referred to as the classic Amsterdam Criteria: 1) HNPCC is diagnosed when 3 or more patients with histologically confirmed colorectal cancer are present in a family line and one is a first relative of the other two, 2) colorectal cancer develops over two generations, and 3) one case is diagnosed at younger than 50 years old \[[@R3]\].

CLINICAL DIAGNOSTIC CRITERIA FOR HNPCC
======================================

Since the Amsterdam Criteria for HNPCC were proposed in 1991, several other diagnostic criteria, including the Japanese Criteria and Bethesda Criteria, have been published. The confusion caused by the different criteria was resolved by revision of the Amsterdam Criteria by the ICG-HNPCC in 1999, to give the new Amsterdam Criteria \[[@R4]\] (Table **[1](#T1){ref-type="table"}**). These criteria address endometrial cancer, small intestinal cancer, urethral cancer, and kidney cancer, in addition to the colorectal cancer included in the classic criteria. Cases not meeting the classic Amsterdam Criteria may meet the new Amsterdam Criteria, and this has resulted in an increased number of cases diagnosed as HNPCC. In addition, discovery of HNPCC has become possible through investigation of familial medical histories of endometrial cancer patients. The revision also recognized the importance of cooperation among gynecologists for identification of HNPCC. One concern with the new criteria is the omission of ovarian, breast and stomach cancer, which may also be associated with HNPCC.

MECHANISM OF HNPCC CARCINOGENESIS AND ASSOCIATION WITH ENDOMETRIAL CANCER
=========================================================================

Six variants of the MMR gene, the causative gene in HNPCC, have been cloned: *hMSH2, hMLH1, hMSH3, hMSH6, hPMS1*and*hPMS2*. An aberration in one of these genes prevents accurate repair of base mismatches produced during DNA replication, resulting in production of a DNA chain of altered length. This phenomenon is called microsatellite instability (MSI) and can lead to an increased frequency of errors in target genes involved in carcinogenesis, resulting in cancerization of the cell. Among the MMR genes, germline mutations of *hMLH1* on chromosome 3 and *hMSH2*on chromosome 2 are thought to cause most cases of HNPCC, but it is unclear if these mutations are also causative for HNPCC-associated endometrial cancer. Mutation of *hMSH6* has also been proposed to be important for development of HNPCC-associated endometrial cancer, but the details are unclear (Fig. **[1](#F1){ref-type="fig"}**) \[[@R5],[@R6]\].

The TGF-β type II receptor, which is involved in inhibition of cell proliferation, and BAX, which is associated with apoptosis induction, are candidate target genes in HNPCC \[[@R7],[@R8]\]. The *E2F* \[[@R9]\], *β-catenin* \[[@R10]\] and *TCF-4* \[[@R11]\] genes are also candidates, but the frequencies of aberration of these genes in endometrial cancer are low. Variation of the target gene involved in carcinogenesis in different organs has also been suggested. *PTEN* is also a commonly reported target gene in endometrial cancer \[[@R12]\], but its function remains unclear. Endometrial cancer develops through a mechanism similar to that of HNPCC, but may have unique biological characteristics. An analysis of endometrial cancer as a familial tumor has not been performed and many aspects of the cancer are unclear, including its genetic penetrance.

CLINICAL CHARACTERISTICS OF HNPCC
=================================

The frequency of HNPCC is unclear due to variation among reports, but HNPCC is thought to account for about 5% of all colorectal cancer cases \[[@R13]-[@R18]\] and to have the following clinicopathological characteristics: autosomal dominant inheritance; genetic penetrance of about 85% at 80 years of age; development at a young age; frequent development in the right colon; often poorly differentiated mucinous adenocarcinoma; diploid on cytometric analysis; marked intratumor infiltration of lymphocytes; microsatellite instability; high risk of development of endometrial cancer, urinary tract cancer, and small intestinal cancer; and a favorable prognosis \[[@R19]\]. The reason for the favorable prognosis despite many cases being poorly differentiated mucinous adenocarcinoma is unclear, but may be due to lymphocyte infiltration in the tumor and a low rate of lymph node metastasis. An association between aberration of MMR, the causative gene for HNPCC, and reduced sensitivity to anticancer drugs such as cisplatin has also been reported (Fig. **[2](#F2){ref-type="fig"}**) \[[@R20]\].

GYNECOLOGICAL CANCERS ASSOCIATED WITH HNPCC
===========================================

The close association of endometrial cancer with HNPCC is apparent in the new Amsterdam Criteria. However, other gynecological cancers have also been reported in the first relatives of patients with HNPCC, with the incidence of endometrial cancer being highest at 9-19%, followed by stomach cancer and ovarian cancer at 6-14% and 5-7%, respectively \[[@R21]\]. An association of ovarian cancer with HNPCC has been suggested, but may not be as close as that of endometrial cancer, and a link between breast cancer and HNPCC has also attracted recent attention. Muir-Torre syndrome is an autosomal dominant hereditary disease of concomitant sebaceous gland tumors (adenoma, epithelioma and carcinoma) and malignant visceral tumors, and the incidences of colorectal and urogenital cancers are high among malignant visceral tumors, followed by breast cancer and malignant blood diseases. The lifetime incidence of breast cancer is about 12%. Mutation of the *hMSH2*MMR gene has been found in 2 cases of Muir-Torre syndrome \[[@R22],[@R23]\] and this disease is assumed to have the pathology of hereditary breast cancer and to be a subtype of HNPCC.

ENDOMETRIAL CANCER AND MICOSATELLITE INSTABILITY (MSI)
======================================================

To investigate the status and clinicopathological characteristics of familial endometrial cancer, Banno *et al*. \[[@R24]\] surveyed the familial and medical histories of 385 patients who underwent treatment for endometrial cancer. MSI analysis was performed in 38 of these patients. The familial medical histories showed that 2 of the 385 cases met the new Amsterdam Criteria for HNPCC, giving a rate of HNPCC of about 0.5%. Investigation of familial accumulation of cancer in 890 relatives (439 men and 451 women) of the 38 endometrial cancer patients who underwent MSI analysis revealed high incidences of endometrial cancer, colorectal cancer and ovarian cancer, suggesting that a hereditary factor common to HNPCC is also involved in endometrial cancer. MSI analysis detected the presence of at least one of 5 microsatellite markers (D2S123, D3S1284, D5S404, D9S162, and hMSH2 intron 12) in 12 of the 38 cases (31.6%). This rate is very high compared to MSI in cancers of other organs, demonstrating that abnormal DNA mismatch repair plays an important role in endometrial cancer. The patients with MSI showed a tendency to have double cancer (such as ovarian cancer) compared with patients with microsatellite stability (MSS), although the difference was not significant (27% *vs*. 15%). Regarding prognosis, none of the MSI-positive cases were fatal (0/11, 0%), while 5 MSI-negative (MSS) cases were fatal (5/27, 19%). The difference was not significant, but this tendency is similar to that for HNPCC-associated colorectal cancer. The incidences of moderately differentiated adenocarcinoma G2 (36%) and poorly differentiated adenocarcinoma G3 (18%) tended to be higher in MSI-positive endometrial cancer, although the difference was not significant. These findings appear contradictory with the favorable prognosis, but interestingly they may reflect the biological characteristics of endometrial cancer induced by abnormal DNA mismatch repair \[[@R25]\].

GERMLINE MUTATIONS IN ENDOMETRIAL CANCER PATIENTS WITH FAMILIAL ACCUMULATION OF CANCER
======================================================================================

Hirai *et al*. \[[@R26]\] have recently performed an analysis of germline mutation of three MMR genes (*hMLH1, hMSH2*and *hMSH6*) in 120 patients with endometrial cancer with strongly hereditary familial cancer accumulation or double cancer. Cases in which two or more first relatives had HNPCC-associated tumors (colorectal, endometrial, small intestinal, urethral, and renal pelvic cancers) and stomach, ovarian and breast cancers were designated as Group A, and cases with synchronous or metachronous double cancer of HNPCC-associated tumors (colorectal, endometrial, small intestinal, urethral and renal pelvic cancers) with stomach, ovarian or breast cancer were designated as Group B. Of the 120 cases, 57 were in Group A and 48 in Group B, with 15 in both groups. White blood cell-derived DNA was obtained from the patients and germline mutations were analyzed by direct sequencing of PCR products amplified using primers for all exons of *hMLH1, hMSH2*and *hMSH6.* Germline mutation of the MMR genes was detected in 18 of the 120 cases (15.0%), including 9 of the 57 cases (15.8%) in Group A and 4 of the 48 cases (8.3%) in Group B. A high rate of germline mutation of MMR genes (5/15, 33.3%) was found in cases meeting the criteria for both groups. Mutations were detected in the *hMSH6*gene in 9 cases (50%), the *hMLH1*gene in 5, and the *hMSH2*gene in 4. Mutations of the *hMSH6*gene were concentrated in regions near exons 4-5 and were frameshifts in most cases. The mutations in 7 of the 18 cases had already been reported in the literature and registered in a mutation database, but those in the other 11 cases had not been reported previously \[[@R26]\] (Table **[2](#T2){ref-type="table"}**).

SCREENING OF ENDOMETRIAL CANCER AS HNPCC
========================================

The clinical characteristics of HNPCC in colorectal cancer have gradually been clarified and HNPCC is thought to account for about 5% of all colorectal cancer cases. In contrast, there are only a few reports on endometrial cancer, despite its similar association with MMR gene aberration. An interview of families of 385 patients with endometrial cancer designed to investigate the familial medical histories of cancer revealed 2 patients who met the clinical diagnostic criteria for HNPCC \[[@R24]\]. This indicates that only 0.5% of all endometrial cancer cases are diagnosed as HNPCC, and this rate is markedly lower than that in colorectal cancer.

Microsatellite instability caused by MMR gene aberration is detectable by PCR using microsatellite markers. In screening for HNPCC, use of 5 microsatellite markers (BAT25, BAT26, D5S346, D2S123 and D17S250) is recommended. However, a germline mutation of the MMR gene was detected in only 1 of 12 patients with MSI-positive endometrial cancer (8.3%) and this mutation was a nonsense mutation at codon 100 of the *hMLH1*gene. This mutation was already registered as a functional gene mutation in the Human Gene Mutation Database (HGMD), but this case did not meet the new Amsterdam Criteria for HNPCC \[[@R26]\]. This suggests that current clinical diagnostic criteria and MSI analysis have limited value in screening for HNPCC-associated endometrial cancer.

In Hirai *et al*. \[[@R26]\], germline mutation of the MMR gene was present in 15.8% of patients with endometrial cancer with familial accumulation of cancer, but not meeting the clinical diagnostic criteria for HNPCC. This suggests that MMR gene aberration should be kept in mind in management of patients with a tendency for familial cancer, regardless of the clinical assessment. In particular, familial development of breast, ovarian and stomach cancer, which are not recognized as HNPCC-associated cancers, should be investigated in interviews on familial medical histories. No germline mutation of the MMR gene was present in cases with double cancer alone without familial cancer accumulation, but all double cancers developed earlier than endometrial cancer, which is very interesting from the perspective of screening for endometrial cancer.

The *hMSH6* gene was the most commonly mutated MMR gene found by Hirai *et al*. \[[@R26]\], rather than *hMLH1*or *hMSH2*, which are frequently mutated in colorectal cancer. This finding indicates the importance of *hMSH6* in development of endometrial cancer in HNPCC, and suggests an association between the MMR genotype and the cancer phenotype. Most interestingly, the mutations of *hMSH6*were concentrated in exons 4-5 and were frameshifts. One of the *hMSH6*mutations was a reported functional mutation, but the concentration in exons 4-5 differed from reports in Western patients. Thus, it is possible that this gene mutation is characteristic for HNPCC-associated endometrial cancer (Table **[3](#T3){ref-type="table"}**) \[[@R27],[@R28]\].

FUTURE DIRECTIONS AND CONCLUSION
================================

Many HNPCC-associated cases of endometrial cancer caused by MMR gene aberration do not meet the current clinical diagnostic criteria for HNPCC. Gene analysis focusing on the *hMSH6*gene may allow efficient identification of familial endometrial cancer in cases of endometrial cancer with a tendency of familial accumulation of cancer. The findings that some cases of endometrial cancer are familial tumors and that an abnormal DNA mismatch repair gene is linked to development of the cancer are important for understanding the biological characteristics of endometrial cancer. Thus, it is important to identify and analyze patients with this type of endometrial cancer. However, cases of familial endometrial cancer that meet the current diagnostic criteria account for only 0.5% of all cases, and a close examination of family history is essential in screening for this cancer. An improved understanding of familial tumors among gynecologists and an international large-scale muticenter study are required for further progress, with establishment of a system of genetic tests and counseling for patients. There are currently many aspects of familial endometrial cancer that are unclear, but clarification of the pathology and development of a surveillance system and genetic tests are likely to produce new diagnostic and therapeutic methods for various types of endometrial cancer.
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###### 

Clinical Diagnostic Criteria for HNPCC

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Amsterdam Minimum Criteria (1990)** At least 3 cases of colorectal cancer in relatives (verified pathologically) One is a first degree relative of the other two At least two successive generations should be affected One case of colorectal cancer diagnosed before the age of 50 years old FAP should be excluded
  **Revised Amsterdam Criteria II (1998)**1. At least 3 relatives with an HNPCC-associated cancer (cancer of the colorectum, endometrium, small bowel, ureter or renal pelvis)2-5. As for the minimum criteria
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Eighteen Patients with Endometrial Cancer had MMR Gene Mutations in Germ Cells

  No.    Age   Type    Grade   Stage   Group      Mutation Type                     Report   Double Cancer
  ------ ----- ------- ------- ------- ---------- --------------------------------- -------- ---------------
  K007   42    EM/CL   G2      3c      AB         hMLH1 ex3 codon100 Nonsense       \+       CC(42yo)
  K009   42    EM      G1      1b      A          hMSH6 ex5 codon1085 Frameshift    \+       −
  K017   34    EM      G2      1b      A          hMSH2 ex10 codon554 Missense      −        −
  K023   56    EM      G1      1a      A          hMSH6 ex4 codon795 Frameshift     −        −
  K030   52    EM      G2      3a      A          hMSH6 ex4 codon546 Frameshift     −        −
  K031   54    EM      G2      1a      A          hMSH2 ex11 codon582 Frameshift    −        −
  T004   56    EM      G1      3a      A HNPCC    hMSH2 ex13 codon680 Nonsense      \+       −
  T011   65    AS      G1      3a      B          hMSH6 ex6 codon1163 Missense      −        BC(65yo)
  T016   41    EM      G1      1b      AB HNPCC   hMSH2 ex5 codon288 Nonsense       \+       CC(38,50yo)
  J001   48    EM      G1      1b      AB HNPCC   hMLH1 ex16 codon618 Deletion      \+       CC(44yo)
  J015   53    EM      G1      1a      B          hMSH6 ex4 codon744 Frameshift     −        OvC(53yo)
  J021   55    EM      G1      1b      A          hMSH6 ex4 codon482 Nonsense       −        −
  G001   52    EM      G1      3c      AB HNPCC   hMLH1 ex13 Splicing               \+       CC(48,50yo)
  G030   57    EM      G2      1b      B          hMSH6 ex10 codon1355 Frameshift   −        BC(39yo)
  G032   62    EM      G3      1a      A          hMSH6 ex4 codon487 Frameshift     −        −
  G036   50    EM      G1      1a      A          hMSH6 ex4 codon742 Missense       −        −
  F001   37    EM      G1      1a      B          hMLH1 ex12 codon384 Missense      −        CC(36yo)
  F002   46    EM      G1      1b      AB         hMLH1 ex16 codon618 Deletion      \+       CC(46yo)

CC: Colorectal Cancer, BC: Breast Cancer, OvC: Ovarian Cancer.

###### 

MMR Gene Mutation in Germ Cells in Endometrial Cancer

  Gene             Incidence of Germline Mutation in HNPCC   Incidence of Germline Mutation in HNPCC-Related Endometrial Cancer
  ---------------- ----------------------------------------- --------------------------------------------------------------------
  *hMSH2*          +++                                       \+
  *hMSH3*          −                                         ?
  *hMSH6 (GTBP)*   \+                                        +++
  *hMLH1*          +++                                       ++
  *hPMS1*          \+                                        ?
  *hPMS2*          \+                                        ?
